REPUBLIC of the PHILIPPINES

City of Makati
MECHANISM OF
DRUG NAME
ACTION
As demonstrated in
preclinical models:
Generic name:
Avastin directly binds
Bevacizumab vascular endothelial
growth factor (VEGF) to
Brand name:
inhibit angiogenesis.
Avastin
Bevacizumab acts by
selectively binding
circulating VEGF,
Dosage, Route and thereby inhibiting the
binding of VEGF to its
Frequency:
cell surface receptors.
15 mg/kg IV dose This inhibition leads to a
evaluated in CC in reduction in
combination with either microvascular growth of
cisplatin/paclitaxel or tumor blood vessels and
topotecan/paclitaxel. thus limits the blood
supply to tumor tissues.
15 mg/kg solution for IV
infusion every 3 weeks is
the only dose of Avastin
demonstrated to
significantly increase OS
in women with CC
UNIVERSITY OF MAKATI
COLLEGE OF ALLIED HEALTH STUDIES
J. P. Rizal Extension, West Rembo, Makati City 1215
Telephone No. : (+632) – 881 – 1571
CENTER OF NURSING
DRUG STUDY
SIDE EFFECTS/
INDICATION CONTRAINDICATION NURSING CONSIDERATION
ADVERSE REACTION
Persistent, recurrent, or metastatic Patients were Before:
cervical cancer (CC) classified as having a
According to previous
contraindication if they Assessment & Drug Effects
Avastin, in combination with paclitaxel reports, the most frequent
had at least two
and cisplatin or paclitaxel and topotecan, adverse reactions to
claims within 12  Monitor for S&S of an
is indicated for the treatment of patients bevacizumab are:
months before first infusion reaction
with persistent, recurrent, or metastatic
-hypertension bevacizumab for any (hypersensitivity);
cervical cancer.
of the following infusion should be
-proteinuria, with diagnoses: interrupted in all patients
gastrointestinal perforation with severe infusion
Reference: being the most serious. -severe cardiac
reactions and
disease
Genentech USA, Inc “”Avastin” (2021) -thrombosis appropriate therapy
Retrieved from: -thrombosis, instituted.
-bleeding hemorrhage
https://www.avastin.com/hcp/cc/dosing- During:
usage.html -stroke
-hemoptysis  Monitor BP at least
every 2–3 wk; if
-colon perforation. hypertension develops,
monitor more frequently,
even after
discontinuation of
bevacizumab.

NAME OF PATIENT: DIAGNOSIS: WARD/ROOM:

 REPUBLIC of the PHILIPPINES
City of Makati
UNIVERSITY OF MAKATI
COLLEGE OF ALLIED HEALTH STUDIES
J. P. Rizal Extension, West Rembo, Makati City 1215
Telephone No. : (+632) – 881 – 1571
CENTER OF NURSING

Classification:
Antiangiogenic agents  Withhold drug and
promptly notify physician
for S&S of CHF,
hemorrhage (e.g.,
epistaxis, hemoptysis, or
GI bleeding), or
unexplained abdominal
pain.

After:

 Lab tests: Urinalysis for

proteinuria and 24 h
urine if protein 2+ or
greater.

 Monitor for dizziness,

lightheadedness, or loss
of balance. Take
appropriate safety
measures.

NAME OF PATIENT: DIAGNOSIS: WARD/ROOM:

 REPUBLIC of the PHILIPPINES
City of Makati
UNIVERSITY OF MAKATI
COLLEGE OF ALLIED HEALTH STUDIES
J. P. Rizal Extension, West Rembo, Makati City 1215
Telephone No. : (+632) – 881 – 1571
CENTER OF NURSING
REFERENCE/S:
Tomislav Dragovich, MD, PhD “What is the role of bevacizumab in the treatment of colon cancer” (Apr 15, 2020) Retrieved from: https://reference.medscape.com/drug/avastin-mvasi-
bevacizumab-342257

NAME OF PATIENT: DIAGNOSIS: WARD/ROOM: